Folate-mediated delivery of macromolecular anticancer therapeutic agents

Advanced Drug Delivery Reviews

Volumn 54, Issue 5, 2002, Pages 675-693

  Lu, Yingjuan ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Folate receptor; Gene therapy vectors; Immunotherapeutic agents; Liposomal therapeutic agents; Macromolecular drug targeting; Prodrug activating enzymes

Indexed keywords

BIOLOGICAL ORGANS; BRAIN; MOLECULAR WEIGHT; TISSUE; TUMORS;

THERAPEUTIC AGENTS;

DRUG DOSAGE;

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA GALACTOSIDASE; DOXORUBICIN LIPOSOME CONJUGATE; FOLATE HAPTEN CONJUGATE; FOLATE MOMORDIN CONJUGATE; FOLATE N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; FOLATE PENTETATE IN 111 CONJUGATE; FOLATE PSEUDOMONAS EXOTOXIN CONJUGATE; FOLIC ACID; MACROGOL; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NAKED DNA; PRODRUG; UNCLASSIFIED DRUG; VITAMIN RECEPTOR;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; CANCER CELL CULTURE; CELL SURFACE; CELL TRANSPORT; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG SELECTIVITY; ENDOCYTOSIS; GENE THERAPY; HUMAN; IN VIVO STUDY; LIGAND BINDING; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR UPREGULATION; REVIEW;

ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DRUG CARRIERS; ENDOCYTOSIS; ENZYMES; FOLIC ACID; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MACROMOLECULAR SUBSTANCES; NEOPLASMS; OLIGONUCLEOTIDES; RECEPTORS, CELL SURFACE; TOXINS, BIOLOGICAL;

EID: 0037072555     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00042-X     Document Type: Review

References (93)

1. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41:2001;189-207.
2. Netti P.A., Baxter L.T., Boucher Y., Skalak R., Jain R.K. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res. 55:1995;5451-5458.
3. Torchilin V.P. Drug targeting. Eur. J. Pharm. Sci. 11:(Suppl. 2):2000;S81-91.
4. Nakashima-Matsushita N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 42:1999;1609-1616.
5. M.J. Turk, G.J. Breur, W.R. Widmer, C.M. Paulos, L. Xu, L.A. Grote, P.S. Low, Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis, Arthritis Rheum., in press.
6. Antony A.C. The biological chemistry of folate receptors. Blood. 79:1992;2807-2820.
7. Garin-Chesa P., Campbell I., Saigo P.E., Lewis J.L. Jr., Old L.J., Rettig W.J. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. 142:1993;557-567.
8. Toffoli G., Cernigoi C., Russo A., Gallo A., Bagnoli M., Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer. 74:1997;193-198.
9. Gruner B.A., Weitman S.D. The folate receptor as a potential therapeutic anticancer target. Invest. New Drugs. 16:1998;205-219.
10. Reddy J.A., Low P.S. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carrier Syst. 15:1998;587-627.
11. Sudimack J., Lee R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41:2000;147-162.
12. Shen F., Ross J.F., Wang X., Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 33:1994;1209-1215.
13. Wang X., Shen F., Freisheim J.H., Gentry L.E., Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem. Pharmacol. 44:1992;1898-1901.
14. Kamen B.A., Caston J.D. Properties of a folate binding protein (FBP) isolated from porcine kidney. Biochem. Pharmacol. 35:1986;2323-2329.
15. da Costa M., Rothenberg S.P. Purification and characterization of folate binding proteins from rat placenta. Biochim. Biophys. Acta. 1292:1996;23-30.
16. Shen F., Wu M., Ross J.F., Miller D., Ratnam M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 34:1995;5660-5665.
17. Spiegelstein O., Eudy J.D., Finnell R.H. Identification of two putative novel folate receptor genes in humans and mouse. Gene. 258:2000;117-125.
18. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 73:1994;2432-2443.
19. Wu M., Gunning W., Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. 8:1999;775-782.
20. Weitman S.D., Frazier K.M., Kamen B.A. The folate receptor in central nervous system malignancies of childhood. J. Neurooncol. 21:1994;107-112.
21. Bueno R., Appasani K., Mercer H., Lester S., Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 121:2001;225-233.
22. Toffoli G., Russo A., Gallo A., Cernigoi C., Miotti S., Sorio R., Tumolo S., Boiocchi M. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int. J. Cancer. 79:1998;121-126.
23. Ross J.F., Wang H., Behm F.G., Mathew P., Wu M., Booth R., Ratnam M. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 85:1999;348-357.
24. Reddy J.A., Haneline L.S., Srour E.F., Antony A.C., Clapp D.W., Low P.S. Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood. 93:1999;3940-3948.
25. Weitman S.D., Weinberg A.G., Coney L.R., Zurawski V.R., Jennings D.S., Kamen B.A. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res. 52:1992;6708-6711.
26. Patrick T.A., Kranz D.M., van Dyke T.A., Roy E.J. Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice. J. Neurooncol. 32:1997;111-123.
27. Birn H., Nielsen S., Christensen E.I. Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule. Am. J. Physiol. 272:1997;F70-78.
28. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA. 88:1991;5572-5576.
29. Turek J.J., Leamon C.P., Low P.S. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J. Cell. Sci. 106:1993;423-430.
30. Rothberg K.G., Ying Y.S., Kamen B.A., Anderson R.G. Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J. Cell Biol. 111:1990;2931-2938.
31. Mayor S., Rothberg K.G., Maxfield F.R. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science. 264:1994;1948-1951.
32. Rothberg K.G., Ying Y.S., Kolhouse J.F., Kamen B.A., Anderson R.G. The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway. J. Cell Biol. 110:1990;637-649.
33. Anderson R.G., Kamen B.A., Rothberg K.G., Lacey S.W. Potocytosis: sequestration and transport of small molecules by caveolae. Science. 255:1992;410-411.
34. Wu M., Fan J., Gunning W., Ratnam M. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin. J. Membr. Biol. 159:1997;137-147.
35. Varma R., Mayor S. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature. 394:1998;798-801.
36. Kamen B.A., Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc. Natl. Acad. Sci. USA. 83:1986;5983-5987.
37. Lee R.J., Wang S., Low P.S. Measurement of endosome pH following folate receptor-mediated endocytosis. Biochim. Biophys. Acta. 1312:1996;237-242.
38. Mathias C.J., Wang S., Lee R.J., Waters D.J., Low P.S., Green M.A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med. 37:1996;1003-1008.
39. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., Green M.A. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med. 39:1998;1579-1585.
40. Guo W., Hinkle G.H., Lee R.J. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J. Nucl. Med. 40:1999;1563-1569.
41. Leamon C.P., Low P.S. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov. Today. 6:2001;44-51.
42. Leamon C.P., Low P.S. Cytotoxicity of momordin-folate conjugates in cultured human cells. J. Biol. Chem. 267:1992;24966-24971.
43. Leamon C.P., Pastan I., Low P.S. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J. Biol. Chem. 268:1993;24847-24854.
44. Atkinson S.F., Bettinger T., Seymour L.W., Behr J.P., Ward C.M. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J. Biol. Chem. 276:2001;27930-27935.
45. Lee R.J., Low P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1233:1995;134-144.
46. S.M. Stephenson, P.S. Low, R.J. Lee, Folate receptor mediated targeting of liposomal drugs to cancer cells, Methods Enzymol., in press.
47. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6:2000;1949-1957.
48. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., Low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA. 92:1995;3318-3322.
49. Ginobbi P., Geiser T.A., Ombres D., Citro G. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Anticancer Res. 17:1997;29-35.
50. Li S., Deshmukh H.M., Huang L. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm. Res. 15:1998;1540-1545.
51. Lee R.J., Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J. Biol. Chem. 271:1996;8481-8487.
52. Douglas J.T., Rogers B.E., Rosenfeld M.E., Michael S.I., Feng M., Curiel D.T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. 14:1996;1574-1578.
53. Xu L., Pirollo K.F., Chang E.H. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J. Control. Release. 74:2001;115-128.
54. Stella B., Arpicco S., Peracchia M.T., Desmaele D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 89:2000;1452-1464.
55. Rihova B. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 29:1998;273-289.
56. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47:2001;113-131.
57. Lu J.Y., Lowe D.A., Kennedy M.D., Low P.S. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J. Drug Target. 7:1999;43-53.
58. Kranz D.M., Patrick T.A., Brigle K.E., Spinella M.J., Roy E.J. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. USA. 92:1995;9057-9061.
59. Lu Y., Low P.S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 51:2002;153-162.
60. Leamon C.P., Low P.S. Selective targeting of malignant cells with cytotoxin-folate conjugates. J. Drug Target. 2:1994;101-112.
61. Leamon C.P., DePrince R.B., Hendren R.W. Folate-mediated drug delivery: effect of alternative conjugation chemistry. J. Drug Target. 7:1999;157-169.
62. Shinoda T., Takagi A., Maeda A., Kagatani S., Konno Y., Hashida M. In vivo fate of folate-BSA in non-tumor- and tumor-bearing mice. J. Pharm. Sci. 87:1998;1521-1526.
63. Ward C.M., Acheson N., Seymour L.W. Folic acid targeting of protein conjugates into ascites tumour cells from ovarian cancer patients. J. Drug Target. 8:2000;119-123.
64. Drummond D.C., Hong K., Park J.W., Benz C.C., Kirpotin D.B. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam. Horm. 60:2000;285-332.
65. Vyas S.P., Singh A., Sihorkar V. Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. Crit. Rev. Ther. Drug Carrier Syst. 18:2001;1-76.
66. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
67. Lee R.J., Wang S., Turk M.J., Low P.S. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci. Rep. 18:1998;69-78.
68. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., Zalipsky S. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. 10:1999;289-298.
69. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta. 1113:1992;171-199.
70. Papahadjopoulos D., Gabizon A. Liposomes designed to avoid the reticuloendothelial system. Prog. Clin. Biol. Res. 343:1990;85-93.
71. Vogel K., Wang S., Lee R.J., Chmielewski J., Low P.S. Peptide-mediated release of folate-targeted liposome contents from endosomal compartments. J. Am. Chem. Soc. 118:1996;1581-1586.
72. Rui Y., Wang S., Low P.S., Thompson D.H. Diplasmenylcholine-folate liposomes: an efficient vehicle for intracellular drug delivery. J. Am. Chem. Soc. 120:1998;11213-11218.
73. Qualls M.M., Thompson D.H. Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: intracellular localization and synergistic phototoxicity. Int. J. Cancer. 93:2001;384-392.
74. Guo W., Lee T., Sudimack J., Lee R.J. Receptor-specific delivery of liposomes via folate-PEG-chol. J. Liposome Res. 10:2000;179-195.
75. Mellman I. Endocytosis and molecular sorting. Annu. Rev. Cell Dev. Biol. 12:1996;575-625.
76. Pouton C.W., Lucas P., Thomas B.J., Uduehi A.N., Milroy D.A., Moss S.H. Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids. J. Control. Release. 53:1998;289-299.
77. Reddy J.A., Dean D., Kennedy M.D., Low P.S. Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. J. Pharm. Sci. 88:1999;1112-1118.
78. Turk M.J., Reddy J.A., Chmielewski J.A., Low P.S. Characterization of a novel pH-sensitive peptide that enhances drug release from folate targeted liposomes at endosomal pHs. Biochim. Biophys. Acta. 1559:2002;56-68.
79. Reddy J.A., Low P.S. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J. Control. Release. 64:2000;27-37.
80. Kirpotin D.B., Park J.W., Hong K., Shao Y., Shalaby R., Colbern G., Benz C.C., Papahadjopoulos D. Targeting of liposomes to solid tumors: the case of sterically stabilized anti-HER2 immunoliposomes. J. Liposome Res. 7:1997;391-417.
81. Pizzato M., Blair E., Fling M., Kopf J., Tomassetti A., Weiss R., Takeuchi Y. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. Gene Ther. 8:2001;1088-1096.
82. Reddy J.A., Clapp D.W., Low P.S. Retargeting of viral vectors to the folate receptor endocytic pathway. J. Control. Release. 74:2001;77-82.
83. Mislick K.A., Baldeschwieler J.D., Kayyem J.F., Meade T.J. Transfection of folate-polylysine DNA complexes: evidence for lysosomal delivery. Bioconjug. Chem. 6:1995;512-515.
84. Leamon C.P., Weigl D., Hendren R.W. Folate copolymer-mediated transfection of cultured cells. Bioconjug. Chem. 10:1999;947-957.
85. Guo W., Lee R. Receptor-targeted gene delivery via folate-conjugated polyethylenimine. AAPS PharmSci. 1:1999;E19.
86. Leong K.W., Mao H.Q., Truong-Le V.L., Roy K., Walsh S.M., August J.T. DNA-polycation nanospheres as non-viral gene delivery vehicles. J. Control. Release. 53:1998;183-193.
87. Rihova B. Antibody-targeted polymer-bound drugs. Folia Microbiol. 40:1995;367-384.
88. Yokoyama M., Fukushima S., Uehara R., Okamoto K., Kataoka K., Sakurai Y., Okano T. Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J. Control. Release. 50:1998;79-92.
89. Nishiyama N., Kato Y., Sugiyama Y., Kataoka K. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm. Res. 18:2001;1035-1041.
90. Springer C.J., Niculescu-Duvaz I.I. Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv. Drug Deliv. Rev. 26:1997;151-172.
91. Patrick T.A., Kranz D.M., Zachary J.F., Roy E.J. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors. Int. J. Cancer. 78:1998;470-479.
92. Roy E.J., Cho B.K., Rund L.A., Patrick T.A., Kranz D.M. Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate. Int. J. Cancer. 76:1998;761-766.
93. Rund L.A., Cho B.K., Manning T.C., Holler P.D., Roy E.J., Kranz D.M. Bispecific agents target endogenous murine T cells against human tumor xenografts. Int. J. Cancer. 83:1999;141-149.